Neoadjuvant and Adjuvant Therapy for Non–Small Cell Lung Cancer - 20/12/17
Résumé |
The use of 4 cycles of cisplatin-based adjuvant chemotherapy is now the standard of care for patients with resected stage II and IIIA non–small cell lung cancer. Neoadjuvant chemotherapy lacks the same level of data as adjuvant treatment, but meta-analyses of this approach support its use. Selection of patients who are most likely to benefit from chemotherapy remain elusive. Ongoing adjuvant trials are exploring biomarkers, molecularly targeted agents, postoperative radiation therapy, and immunotherapy.
Le texte complet de cet article est disponible en PDF.Keywords : Adjuvant chemotherapy, Neoadjuvant chemotherapy, Postoperative radiation therapy
Plan
| Disclosure Statement: Dr H.A. Wakelee has consulting relationships with Peregrine, ACEA, Pfizer, Helsinn, Genentech (uncompensated) and performs research (with funds paid to her institution) with Clovis, Exelixis, AstraZeneca/MedImmune, Genentech/Roche, BMS, Gilead, Novartis, Xcovery, Pfizer, Celgene, Gilead, Pharmacyclics, and Eli Lilly and Company. Drs J.C. Chuang and Y Liang have nothing to disclose. |
Vol 31 - N° 1
P. 31-44 - février 2017 Retour au numéro
Article précédent
- Lung Cancer Biomarkers
- Pamela Villalobos, Ignacio I. Wistuba
- Treatment of Locally Advanced Non–Small Cell Lung Cancer
- Kit Tam, Megan Daly, Karen Kelly
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?